Eden Research Plc · LSE:EDEN
Eden Research — FY2024 Earnings Presentation
15 slides from Eden Research's earnings presentation, May 2025
Slide 1: Eden Research plc
Eden Research plc Eden Research plc is a leader in sustainable biopesticide and biocontrol technology. 2024 Preliminary Results presentation May 2025
Slide 2: Executive team
Executive team 2 Sean Smith Alex Abrey Chief Executive Officer Chief Financial Officer Over 25 years experience in the Experienced Financial Director to a speciality chemicals and industrial diverse range of businesses including biotechnology industries financial and management consultancy ‐ 10+ yea
Slide 3: Company information
Company information 3 Key statistics Eden is the only UK quoted (AIM: EDEN) company focused on plant-derived biopesticides for sustainable agriculture Regulatory Crop uses Intellectual property and Multiple regulatory expertise in plant-derived clearances (EU, US, AUS, NZ) approvals sustainable chem
Slide 4: Core business, IP & unique selling proposition
Core business, IP & unique selling proposition 4 Eden’s focus is on developing plant-derived biopesticides using its two proprietary technology platforms: $11bn 36 The global biopesticides Number of pesticides • Plant-derived (terpene) active ingredients market is projected to banned in the EU since
Slide 5: 2024 Commercial and Operational Highlights
2024 Commercial and Operational Highlights 5 • Authorisation for Mevalone® received in the key state of California. • Mevalone® authorised for use in multiple new crops and fungal pathogens in Spain. • Authorisation for Mevalone® received in Germany and Czechia. • 140+ insecticides field trials run
Slide 6: Financials
Financials 6 • Significant increase in revenue: 2025 2024 2023 2022 • 34% vs 2023 forecast YOY % YOY % YOY % • Significant increase in product sales: £m £m £m £m change change change • 38% vs 2023 Revenue 5.0 16 4.3 34 3.2 78 1.8 • Strong financial position: Product sales 4.6 28 3.6 38 2.6 53 1.7 •
Slide 7: Upcoming news-flow
Upcoming news-flow 7 • Major label extensions for Mevalone in various countries (e.g. France) Q2/3, 2025 • Full approval of Ecovelex in Europe H2, 2025 • Commercial agreement(s) for insecticide H2, 2025 • Emergency Use applications for Cedroz (wireworm) and Ecovelex* H2, 2025 • Commercial agreement(
Slide 8: Product development roadmap
Product development roadmap 8 Late Product Target Crops/markets Discovery Early development development Partnerships Mevalone (fungicide) Botrytis, powdery High-value fruits & mildew, downy vegetables (EU, US, mildew Oceania) Cedroz (nematicide) Nematodes High-value fruits & vegetables (EU) Ecovelex
Slide 9: Revenue potential by product
Revenue potential by product 9 Total Total EU US (EU/US) (global) • Illustration based upon current €m €m €m €m and in-process labels, but ignoring future expansions of indicated Mevalone (botrytis) 3 3 6 15 uses • Peak sales generally occur 3 years Mevalone (downy mildew) 8* - 8 38 from the launch
Slide 10: Key partners
Key partners 10 Corteva Agriscience is a publicly traded agricultural company that produces seeds, crop protection products, and digital services. The company was formed in 2019 when DuPont Crop Protection, DuPont Pioneer, and Dow AgroSciences merged and in 2023 had revenue of $17bn. Established in
Slide 11: Market Adoption and Regulatory Overview
11 Market Adoption and Regulatory Overview Why do farmers use Eden’s products? ‐ Mevalone, Cedroz and Ecovelex are all proven products ‐ They are: ‐ are a reliable alternative to conventional control ‐ provide phased release for prolonged effects ‐ are easy to use and apply ‐ provide improved stabil
Slide 12: Institutional and Directors' Shareholdings
Institutional and Directors’ Shareholdings 12 % of the issued ordinary Share purchases Shareholder Number of shares share capital 2025 Gresham House Asset Management Limited 52,882,786 9.92% Octopus Investments 41,551,047 7.79% Sipcam Oxon S.p.A. 39,285,138 7.37% Canaccord Genuity Wealth Management
Slide 13: Case Study: Ecovelex Bird repellent seed treatment
Ecovelex Case Study: Ecovelex 13 Bird repellent seed treatment Background Current status Ecovelex has been sold in Italy in the Ecovelex is a biological bird repellent seed Semi-field studies showed past two years under emergency use treatment initially for use on maize. good efficacy authorisation
Slide 14: Investment summary
Investment summary 14 01 Commercialisation Eden is well-placed to further commercialise multiple products in order to 05 Increase number of commercial partners Opportunity to increase the number accelerate growth of commercial partners and diversify product range 02 Technology exploitation Ability t
Slide 15: Thank you
THANK YOU CONTACT: INFO@EDENRESEARCH.COM LSE: EDEN.L